

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

WORLD HEALTH ORGANIZATION
TECHNICAL REPORT SERIES

No. 329

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Eighteenth Report

WORLD HEALTH ORGANIZATION

GENEVA

1966

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Geneva, 27 September - 2 October 1965

Members : *

- Dr D. R. Bangham, Director, Department of Biological Standards, National Institute for Medical Research, Mill Hill, London, England
Dr H. H. Cohen, Director, National Institute of Public Health, Utrecht, Netherlands
Dr J. Desbordes, Director, Department of Microbiology, National Laboratory of Public Health, Paris, France
Professor G. Heymann, Acting Director, Paul-Ehrlich Institute, Frankfurt-am-Main, Germany (*Rapporteur*)
Dr P. Krag, Director, Department of Biological Standards, Statens Seruminstitut, Copenhagen, Denmark
Dr A. Lafontaine, Director, Institute of Hygiene and Epidemiology, Brussels, Belgium (*Chairman*)
Dr R. Murray, Director, Division of Biologics Standards, Department of Health, Education and Welfare, Public Health Service, Bethesda, Md., USA (*Vice-Chairman*)
Dr J. B. Shrivastav, Deputy Director-General of Health Services, Ministry of Health of India, New Delhi, India
Dr G. V. Vygodchikov, Head of Department, Institute of Epidemiology and Microbiology (N. F. Gamaleja), Moscow, USSR
Dr A. E. Wilhelmi, Division of Basic Health Services, Department of Biochemistry, Emory University, Atlanta, Ga, USA

Representative of the Food and Agriculture Organization of the United Nations :

- Mr H. I. Field, Director, Central Veterinary Laboratories and Veterinary Investigation Services, Weybridge, Surrey, England

Secretariat :

- Professor D. G. Evans, London School of Hygiene and Tropical Medicine, London, England (*Consultant*)
Mr E. C. Hulse, Director, Department of Biological Standards, Central Veterinary Laboratory, Weybridge, Surrey, England (*Consultant*)
Dr A. N. Klimov, Director, Division of Biology and Pharmacology, WHO, Geneva
Mr J. W. Lightbown, Department of Biological Standards, National Institute for Medical Research, Mill Hill, London, England (*Consultant*)
Dr A. S. Otschoorn, Chief Medical Officer, Biological Standardization, WHO, Geneva (*Secretary*)
Dr J. Spaun, Deputy Director, Department of Biological Standards, Statens Seruminstitut, Copenhagen, Denmark (*Consultant*)
Dr W. W. Wright, Deputy Director, Division of Antibiotics and Insulin Certification, Bureau of Scientific Standards and Evaluation, Food and Drug Administration, Washington, USA (*Consultant*)

* Unable to attend :

- Dr J. H. S. Gear, Director, South African Institute for Medical Research, Johannesburg, South Africa ; Dr P. de Goes, Director, Institute of Microbiology, University of Brazil, Rio de Janeiro, Brazil ; Dr P. A. Versilova, Institute of Epidemiology and Microbiology (N. F. Gamaleja), Moscow, USSR.

© World Health Organization 1966

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization.

For rights of reproduction or translation of WHO publications *in toto*, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

PRINTED IN SWITZERLAND

CONTENTS

	Page
GENERAL	5
PHARMACOLOGICAL	
Antibiotics	
1. Novobiocin	6
2. Ristocetin	6
3. Nystatin	6
4. Paromomycin	6
5. Rolitetracycline	7
6. Colistin	7
7. Colistin methane sulfonate	7
8. Procaine benzylpenicillin in oil with aluminium monostearate	7
9. Tylosin	8
10. Hygromycin B	8
11. Cefalotin	8
12. Lincomycin	8
13. Rifamycin SV	9
14. Semisynthetic penicillins	9
15. Other antibiotics	9
Hormones, Vitamins, Enzymes	
16. Human growth hormone	10
17. Angiotensins and renins	10
18. Erythropoietin	10
19. Heparins	10
20. Streptokinase — streptodornase	11
21. Urokinase	11
22. Other components of the blood coagulation and fibrinolytic systems	11
23. Human insulin	11
24. Human thyrotrophin	12
25. Haemoglobin	12
26. Biological standards and WHO chemical reference substances	12
IMMUNOLOGICAL	
Antigens	
27. BCG vaccine	13
28. Old tuberculin	14
29. Other tuberculins	14
30. Rabies vaccine	15
31. Typhoid vaccine	15
32. Paratyphoid vaccines	15
33. Cholera vaccine	15
34. Tetanus toxoid (adsorbed)	16
35. <i>Clostridium oedematiens</i> (alpha) toxoid	16
36. Measles vaccine (inactivated)	16
37. Newcastle disease vaccine (live)	16
38. Cardiolipin and lecithin (egg)	16

	Page
Antibodies	
39. Anti- <i>Brucella abortus</i> serum	17
40. Tetanus antitoxin for flocculation test	17
41. <i>Clostridium botulinum</i> type F antitoxin	17
42. Anti-Newcastle-disease serum	17
43. Snake antivenins	18
44. Anti-smallpox serum	18
45. Anti-rubella serum	18
46. Anti-anthrax serum	19
47. Gas-gangrene antitoxin (oedematiens)	19
48. Anti-staphylococcal P-V leucocidin serum	19
49. Rheumatoid arthritis serum	20
50. Blood-typing sera	20
51. Long-acting thyroid stimulator	20
52. Other auto-antibodies	20
Miscellaneous	
53. Opacity reference preparation	21
Biological Reference Reagents	
54. Anti-tick-borne encephalitis sera	21
55. Enterovirus antisera	21
56. Adenovirus antisera	21
INTERNATIONAL REQUIREMENTS FOR BIOLOGICAL SUBSTANCES	
57. Requirements for dried BCG vaccine	22
58. Requirements for measles vaccines	22
59. Revised requirements for biological substances	22
60. Requirements for other biological substances	23
Annex 1. Requirements for dried BCG vaccine (Requirements for biological substances No. 11)	25
Annex 2. Requirements for measles vaccine (live) and measles vaccine (inactivated) (Requirements for biological substances No. 12)	52
Annex 3. Requirements for biological substances (general description and list of published documents)	91
Annex 4. List of international biological standards and international biological reference preparations	93
Annex 5. List of international biological reference reagents	124
Annex 6. List of proposed international biological standards, international biological reference preparations and international biological reference reagents	126
Annex 7. Discontinued international biological standards	130

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Eighteenth Report

The WHO Expert Committee on Biological Standardization met in Geneva from 27 September to 2 October 1965.

Dr P. Dorolle, Deputy Director-General, on behalf of the Director-General, welcomed the members of the Committee, as well as the representative of the Food and Agriculture Organization of the United Nations.

Recalling the long traditions of the work on biological standardization, the Deputy Director-General stated that most of the members of the Committee had had long association with it and could be depended on to maintain the high standard expected of the Committee. Referring briefly to the agenda before the Committee, he observed that with successive Expert Committees the topics to be considered appeared to increase both in number and in scope. The increasing responsibility taken by these Committees for the formulation of international requirements for biological substances was one of their most important progressive developments.

The Deputy Director-General also referred to a resolution of the Eighteenth World Health Assembly¹ recommending that Member States of WHO should recognize officially certain international standards and units enumerated in the resolution, this list superseding a similar list included in a resolution of a previous World Health Assembly². These resolutions indicated the interest and recognition by member countries of the work of biological standardization. The use and application of biological standards and of requirements for biological substances were important nationally in medical and public health practice, and had international implications as well, for example in large-scale eradication programmes against communicable diseases and in certain aspects of international quarantine.

¹ *Off. Rec. Wld Hlth Org.*, 1965, **143**, 5 (Resolution WHA18.7).

² World Health Organization (1963) *Handbook of resolutions and decisions of the World Health Assembly and the Executive Board*, 7th ed., Geneva, p. 13 (Resolution WHA3.8).

PHARMACOLOGICAL

ANTIBIOTICS

1. Novobiocin

The Committee noted¹ that in accordance with the authorization in its sixteenth report² the National Institute for Medical Research, London, had established the International Standard for Novobiocin, which replaces the International Reference Preparation, and with the agreement of the participants had defined the International Unit for Novobiocin as the activity contained in 0.001031 mg of the International Standard for Novobiocin.

2. Ristocetin

The Committee noted³ that the manufacture of ristocetin had been discontinued and concluded that the collaborative assay of the International Reference Preparation of Ristocetin, requested in its seventeenth report,⁴ was now unnecessary.

3. Nystatin

The Committee noted⁵ that the stability studies of the International Standard for Nystatin, requested in its sixteenth report,² had not so far revealed any undue instability.

4. Paromomycin

The Committee noted⁶ that in accordance with the authorization in its seventeenth report⁴ the International Reference Preparation of Paromomycin had been established.

The Committee requested the National Institute for Medical Research, London, to organize a limited collaborative study since the material was part of a batch serving as the only existing national standard. The Committee authorized the National Institute for Medical Research to define the international unit with the agreement of the participants.

¹ Unpublished working document WHO/BS/766.

² *Wld Hlth Org. techn. Rep. Ser.*, 1964, 274.

³ Unpublished working document WHO/BS/759.

⁴ *Wld Hlth Org. techn. Rep. Ser.*, 1964, 293.

⁵ Unpublished working document WHO/BS/777.

⁶ Unpublished working document WHO/BS/761.

5. Rolitetracycline

The Committee noted ¹ the results that had been obtained when the preparation of rolitetracycline referred to in its seventeenth report ² was compared with two national standards and requested that it be compared with other national standards.

6. Colistin

The Committee noted ³ that a sufficient quantity of the batch of colistin sulfate referred to in its seventeenth report ² had been obtained and that in accordance with the authorization in that report the material had been established as the International Reference Preparation of Colistin and that a collaborative assay would be arranged.

7. Colistin Methane Sulfonate

The Committee noted ³ that the sample of colistin sodium methane sulfonate referred to in its seventeenth report ² had been compared with a number of other samples obtained from the two countries in which colistin sodium methane sulfonate is made. The Committee was informed that there were only minor differences between the various samples tested and that only one international reference preparation would be required. The Committee therefore requested the National Institute for Medical Research, London, to obtain a sufficient quantity of the material originally examined, and to distribute the material into ampoules. The Committee authorized the National Institute for Medical Research to establish the material as the International Reference Preparation of Colistin Methane Sulfonate and to arrange a collaborative assay.

8. Procaine Benzylpenicillin in Oil with Aluminium Monostearate

The Committee noted ⁴ the progress of the collaborative study, requested in its seventeenth report, ² of the material intended to replace the International Reference Preparation of Procaine Benzylpenicillin in Oil with Aluminium Monostearate. The Committee authorized the National Institute for Medical Research, London, to establish this material as the second International Reference Preparation of Procaine Benzylpenicillin in Oil with Aluminium Monostearate on the basis of the results of the collaborative study.

¹ Unpublished working document WHO/BS/760.

² *Wld Hlth Org. techn. Rep. Ser.*, 1964, 293.

³ Unpublished working document WHO/BS/764.

⁴ Unpublished working document WHO/BS/765.

The Committee also noted ¹ that studies of the stability of benzylpenicillin in serum samples were in progress.

9. Tylosin

The Committee noted ² that in accordance with the authorization in its seventeenth report ³ the International Reference Preparation of Tylosin had been established. On the basis of the results of the collaborative assay the Committee defined the International Unit for Tylosin as the activity contained in 0.001 mg of the International Reference Preparation of Tylosin.

10. Hygromycin B

The Committee noted ⁴ that in accordance with the authorization in its seventeenth report ³ the International Reference Preparation of Hygromycin B had been established. On the basis of the results of the collaborative assay, the Committee defined the International Unit for Hygromycin B as the activity contained in 0.0008928 mg of the International Reference Preparation of Hygromycin B.

11. Cefalotin

The Committee noted ⁵ that in accordance with the request in its seventeenth report ³ the National Institute for Medical Research, London, had obtained a quantity of sodium cefalotin suitable to serve as an international reference preparation.

The Committee established this material as the International Reference Preparation of Cefalotin and requested the National Institute for Medical Research to organize a limited collaborative study, since the material was part of a batch serving as the only existing national standard.

The Committee authorized the National Institute for Medical Research to define the international unit with the agreement of the participants.

12. Lincomycin

The Committee noted ⁵ that in accordance with the request in its seventeenth report ³ the National Institute for Medical Research, London, had obtained a quantity of lincomycin hydrochloride suitable to serve as an international reference preparation.

¹ Unpublished working document WHO/BS/765.

² Unpublished working document WHO/BS/785.

³ *Wld Hlth Org. techn. Rep. Ser.*, 1964, 293.

⁴ Unpublished working document WHO/BS/786.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30868

